@BioWestlake Profile picture

WestlakeVillageBioPartners

@BioWestlake

Helping entrepreneurs in life sciences do things that have never been done before.

Similar User
Timmerman Report photo

@timmermanreport

Biocom California | Los Angeles photo

@BiocominLA

ACELYRIN photo

@ACELYRIN

Dan Gober photo

@BiocomLAExecDir

The Climate Pledge photo

@climatepledge

Dina Lozofsky photo

@WeirdCombin8n

The Lundquist Institute photo

@the_lundquist

UCLA TDG photo

@UCLATDG

David J. Whelan » #LongLA photo

@djwhelan

California Biotech photo

@CABiotech

aleph photo

@aleph

Neuron23 photo

@official_N23

Biocom California | San Diego photo

@BiocominSD

Welcome to Patricia Turney, who has joined Westlake-backed ACELYRIN as Chief Technical Operations Officer. Patricia is an accomplished supply chain, manufacturing, and QC leader who will support the advancement of ACELYRIN’s programs through late-stage clinical trials.

We’re excited to welcome Patricia Turney as CTOO. She will join our Sr. Leadership Team to oversee technical operations, CMC regulatory, corporate quality & facilities. We look forward to adding her expertise during a time of growth. Welcome, Patricia! acelyrin.com/press/acelyrin…



WestlakeVillageBioPartners Reposted

We’re excited to welcome Patricia Turney as CTOO. She will join our Sr. Leadership Team to oversee technical operations, CMC regulatory, corporate quality & facilities. We look forward to adding her expertise during a time of growth. Welcome, Patricia! acelyrin.com/press/acelyrin…


Congratulations Westlake-backed @CapsidaBio and KateTx on their strategic partnership to leverage Capsida's expertise and #AAV manufacturing capabilities to enable KateTx's initial internal portfolio of muscle and heart disease programs. Read more: tinyurl.com/5n83xz23


Congratulations to Mira Chaurushiya, Ph.D., and David Allison, Ph.D. These leaders, alongside Beth Seidenberg, M.D., will manage our third fund of $450 million to incubate and grow early stage next-generation #biotechnology companies. Read more: bit.ly/3XVyd6s

Tweet Image 1
Tweet Image 2

Beth Seidenberg on the launch of our third fund of $450 million to incubate and grow early stage next-generation #biotechnology companies in the #LosAngeles region and beyond. Read more: bit.ly/3XVyd6s #venturecapital #biotechinvesting

Tweet Image 1

Congratulations to our next generation of leaders: Mira Chaurushiya, Ph.D., and David Allison, Ph.D., joining Beth Seidenberg, M.D. as managing directors. These leaders will work together to build great companies from the ground up. Read more: lnkd.in/gRY4YYJW

Tweet Image 1

Westlake-backed Kate Therapeutics debuts with $51 million Series A to develop next-generation genetic medicines to treat muscle and heart diseases. #genetherapy Read the press release: bit.ly/42wDOkv


We're thrilled to share that Mira Chaurushiya, Managing Director at Westlake Village BioPartners, has been named one of Endpoints News' LGBTQ+ biopharma leaders for 2023. Congratulations, Mira! Read the article: bit.ly/3ClDhqB #pridemonth #biopharma


Congratulations to Westlake-backed ACELYRIN, INC. for appointing Henry Gosebruch to the Company's board of directors. You can read the news release here: prn.to/3M1lVFz

Tweet Image 1

Congratulations to Westlake-backed @ArsenalBio on their collaboration with @thermofisher Scientific to support clinical manufacturing of autologous T-cell therapies. Read the press release: bwnews.pr/3nxAWoo bit.ly/3Zkrja0

Tweet Image 1

Don’t miss Sean Harper’s panel at the Greater Conejo Valley Chamber Regional Economic Forecast on March 10, and keynote by Matthew Fienup, Executive Director of CERF, California Lutheran University. For more information and to register, visit bit.ly/3SOZ8hL.

Tweet Image 1

Congratulations to Westlake-backed Neuron23 on initiating dosing in a Phase 1 clinical trial of NEU-723.

Today, Neuron23 announced that we’ve initiated dosing in a Phase 1 clinical trial of NEU-723 – a highly potent and selective brain penetrant LRRK2 inhibitor – for the treatment of Parkinson’s disease. Read more: bit.ly/3DLe7CU #parkinsonsdisease #LRRK2

Tweet Image 1


Westlake-backed @ArsenalBio announced its first patient has been dosed in a Phase 1 clinical trial of AB-1015, in development as a treatment for ovarian cancer. ArsenalBio will provide more details January 10 at the J.P. Morgan 41st Annual Healthcare Conference.

The first patient has been dosed with AB-1015 in a Phase 1, first-in-human clinical trial for patients with ovarian cancer that is resistant to platinum-based regimens. It is our first internally discovered T cell medicine to enter clinical development: shorturl.at/iwT03



We’re thrilled to announce the launch of Westlake-backed Dantari Inc., with $47 million Series A. Proceeds from the financing will support advancement of Dantari’s best-in-class next-gen targeted therapeutics for cancers and other diseases. Learn more: bit.ly/3UAWTOo


Today, Weslake-backed ACELYRIN, INC. announced the addition of two veteran C-suite leaders to its team. Read the full press release here: bit.ly/3tiodFQ


Join Westlake’s Mira Chaurushiya, Ph.D. and other biotech leaders on Tuesday, November 1 as they discuss this year’s turbulent market and what the future ahead might look like. Learn more about the topics and speakers here: bit.ly/3DCoPfq

Tweet Image 1

Join Westlake’s Mira Chaurushiya, Ph.D. and other biotech leaders on Tuesday, November 1 as they discuss this year’s turbulent market and what the future ahead might look like. Learn more about the topics and speakers here: bit.ly/3DCoPfq

Tweet Image 1

Congratulations to Mira Chaurushiya, PhD, Senior Partner at Westlake Village BioPartners, for making @BusinessInsider's list of the top 16 pioneers in biotech venture capital. Read the full article here: bit.ly/3s3lijS

Tweet Image 1

Loading...

Something went wrong.


Something went wrong.